<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="199" ids="26708">Sodium</z:chebi> <z:chebi fb="1" ids="30762">salicylate</z:chebi> is an inexpensive, readily available <z:chebi fb="1" ids="35472">anti-inflammatory agent</z:chebi> which inhibits NF-κB in in vitro models </plain></SENT>
<SENT sid="1" pm="."><plain>We examined whether it was possible to safely achieve and maintain <z:chebi fb="1" ids="30762">salicylate</z:chebi> levels known to inhibit NF-κB in vitro in 11 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> taking <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="1" ids="30762">salicylate</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Most patients achieved the target blood <z:chebi fb="1" ids="30762">salicylate</z:chebi> level (20-30mg/dL) with acceptable toxicity, including reversible grade 1/2 elevations of hepatic transaminases (n=4) and <z:e sem="disease" ids="C0235280" disease_type="Disease or Syndrome" abbrv="">ototoxicity</z:e> (n=4) </plain></SENT>
<SENT sid="3" pm="."><plain>One patient had grade 3/4 elevations in AST/ALT </plain></SENT>
<SENT sid="4" pm="."><plain>This study suggests that <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="1" ids="30762">salicylate</z:chebi> may be safely combined with conventional chemotherapy regimens which are not associated with significant <z:e sem="disease" ids="C0235280" disease_type="Disease or Syndrome" abbrv="">ototoxicity</z:e> or <z:e sem="disease" ids="C0235378,C0348754" disease_type="Disease or Syndrome;Injury or Poisoning" abbrv="">hepatotoxicity</z:e> </plain></SENT>
</text></document>